Core Viewpoint - CollPlant Biotechnologies has announced the development of the first fully humanized 3D bioprinted skin model using its proprietary plant-derived recombinant human collagen (rhCollagen), which offers a sustainable alternative to animal testing for preclinical research and has broad applications in cosmetic and pharmaceutical testing, disease modeling, and drug development [1][7]. Group 1: Technology and Innovation - The 3D bioprinted skin model integrates CollPlant's rhCollagen-based bioinks with essential human skin cell types, enabling the evaluation of drug delivery in a non-animal model [2][7]. - The use of plant-derived rhCollagen allows for high-throughput production of personalized human skin models, which can be applied in regenerative medicine and other medical fields [2][3]. Group 2: Company Overview - CollPlant is focused on regenerative and aesthetic medicine, utilizing 3D bioprinting technologies for tissue repair and medical aesthetics, with products based on its proprietary rhCollagen [4]. - The company has a development and commercialization agreement with Allergan, an AbbVie company, for dermal and soft tissue fillers, indicating its strategic partnerships in the market [5]. Group 3: Market Implications - The innovative skin model represents a significant advancement in reducing animal testing and enhancing the ethical standards of preclinical research, which could lead to broader acceptance and application in the cosmetic and pharmaceutical industries [1][7]. - The results from Mayo Clinic's research validate the potential of rhCollagen-based bioinks for various applications, including in vitro 3D models and regenerative medicine [3].

Core Insights - CollPlant Biotechnologies is advancing its photocurable dermal filler into clinical trials following positive results from its non-clinical program, marking a significant milestone in aesthetic medicine [1][3] - The new dermal filler combines hyaluronic acid with a modified form of recombinant human collagen (rhCollagen), providing both immediate and long-lasting aesthetic benefits [2][3] Product Development - The photocurable dermal filler is administered as a viscoelastic gel and is stabilized using a proprietary illumination device, transforming into a semi-solid implant upon light activation [2][3] - CollPlant's non-clinical program included a one-year in vivo study confirming long-term durability and biocompatibility assessments that comply with international standards, establishing a strong foundation for clinical advancement [3] Strategic Partnerships - In 2021, CollPlant entered into a development and global commercialization agreement with Allergan, an AbbVie company, which is a leader in the dermal filler market [5]